



**BlueCross BlueShield**  
of Oklahoma

If a conflict arises between a Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. Blue Cross and Blue Shield of Oklahoma may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSOK has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association, Current Procedural Terminology, CPT® Assistant, Healthcare Common Procedure Coding System, ICD-10 CM and PCS, National Drug Codes, Diagnosis Related Group guidelines, Centers for Medicare and Medicaid Services National Correct Coding Initiative Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

## **Immune Cell Function Assay**

**Policy Number:** CPCPLAB028

**Version 1.0**

**Approval Date:** Jan. 12, 2026

**Plan Effective Date:** May 1, 2026

## Description

The Plan has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

## Reimbursement Information:

1. Use of an immune cell function assay to monitor and predict immune function after solid organ transplantation **may be reimbursable**.
2. An immune cell function assay **is not reimbursable** for all other indications.

## Procedure Codes

The following is not an all-encompassing code list. The inclusion of a code does not guarantee that it is a covered service or eligible for reimbursement.

| Codes               |
|---------------------|
| 81560, 86352, 0018M |

## References:

1. Buttgereit F, Burmester GR, Brand MD. Bioenergetics of immune functions: fundamental and therapeutic aspects. *Immunology today*. 2000;21(4):192-9. doi:10.1016/S0167-5699(00)01593-0
2. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. *The Journal of allergy and clinical immunology*. 2015;136(5):1186-205.e1-78. doi:10.1016/j.jaci.2015.04.049
3. Butte MJ. Laboratory evaluation of the immune system. Updated January 27, 2025. <https://www.uptodate.com/contents/laboratory-evaluation-of-the-immune-system>
4. Bonilla FA. Interpretation of lymphocyte proliferation tests. *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology*. 2008;101(1):101-4. doi:10.1016/s1081-1206(10)60842-3
5. Fernandez-Ruiz M, Kumar D, Humar A. Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation. *Clinical & translational immunology*. 2014;3(2):e12. doi:10.1038/cti.2014.3
6. Notarangelo LD. Primary immunodeficiencies. *The Journal of allergy and clinical immunology*. 2010;125(2 Suppl 2):S182-94. doi:10.1016/j.jaci.2009.07.053
7. Oliveira JB, Fleisher TA. Laboratory evaluation of primary immunodeficiencies. *The Journal of allergy and clinical immunology*. 2010;125(2 Suppl 2):S297-305. doi:10.1016/j.jaci.2009.08.043
8. Picard C, Al-Herz W, Bousfiha A, et al. Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological

- Societies Expert Committee for Primary Immunodeficiency 2015. *Journal of clinical immunology*. 2015;35(8):696-726. doi:10.1007/s10875-015-0201-1
9. Vella J. Transplantation immunobiology. Updated April 9, 2024. <https://www.uptodate.com/contents/transplantation-immunobiology>
  10. Zhang W, Zhong H, Zhuang L, et al. Peripheral blood CD4(+) cell ATP activity measurement to predict HCC recurrence post-DCD liver transplant. *International journal of clinical practice*. 2016;70 Suppl 185(Suppl Suppl 185):11-6. doi:10.1111/ijcp.12811
  11. Sottong PR, Rosebrock JA, Britz JA, Kramer TR. Measurement of T-lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. *Clinical and diagnostic laboratory immunology*. 2000;7(2):307-11. doi:10.1128%2Fcdli.7.2.307-311.2000
  12. Ashokkumar C, Gupta A, Sun Q, et al. Allospecific CD154+ T cells identify rejection-prone recipients after pediatric small-bowel transplantation. *Surgery*. 2009;146(2):166-73. doi:10.1016/j.surg.2009.04.006
  13. Ashokkumar C, Soltys K, Mazariegos G, et al. Predicting Cellular Rejection With a Cell-Based Assay: Preclinical Evaluation in Children. *Transplantation*. 2017;101(1):131-140. doi:10.1097/tp.0000000000001076
  14. Sindhi R, Ashokkumar C, Higgs BW, et al. Profile of the Pleximmune blood test for transplant rejection risk prediction. *Expert review of molecular diagnostics*. 2016;16(4):387-93. doi:10.1586/14737159.2016.1139455
  15. Intellicyt. Immune Cell Function Assays. 2024;
  16. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. *Transplantation*. 2006;82(5):663-8. doi:10.1097/01.tp.0000234837.02126.70
  17. Ling X, Xiong J, Liang W, et al. Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. *Transplantation*. 2012;93(7):737-43. doi:10.1097/TP.0b013e3182466248
  18. Wang Z, Liu X, Lu P, et al. Performance of the ImmuKnow assay in differentiating infection and acute rejection after kidney transplantation: a meta-analysis. *Transplantation proceedings*. 2014;46(10):3343-51. doi:10.1016/j.transproceed.2014.09.109
  19. Jo Y, Lim J, Kim Y, Han K, Min WS, Oh EJ. CD4 T-cell function assay using Cylex ImmuKnow and lymphocyte subset recovery following allogeneic hematopoietic stem cell transplantation. *Transplant immunology*. 2015;33(2):78-83. doi:10.1016/j.trim.2015.09.001
  20. Ravaioli M, Neri F, Lazzarotto T, et al. Immunosuppression Modifications Based on an Immune Response Assay: Results of a Randomized, Controlled Trial. *Transplantation*. 2015;99(8):1625-32. doi:10.1097/tp.0000000000000650
  21. Piloni D, Magni S, Oggionni T, et al. Clinical utility of CD4+ function assessment (ViraCor-IBT ImmuKnow test) in lung recipients. *Transplant immunology*. 2016;37:35-9. doi:10.1016/j.trim.2016.04.001
  22. Chiereghin A, Petrisli E, Ravaioli M, et al. Infectious agents after liver transplant: etiology, timeline and patients' cell-mediated immunity responses. *Medical microbiology and immunology*. 2017;206(1):63-71. doi:10.1007/s00430-016-0485-7
  23. Liu W, Wang K, Zhao YH, Song GP, Gao W, Li DH. Clinical relevance of a CD4(+) T cell immune function assay in the diagnosis of infection in pediatric living-donor

- liver transplantation. *Exp Ther Med*. 2019;18(5):3823-3828. doi:10.3892/etm.2019.8003
24. Weston MW, Rinde-Hoffman D, Lopez-Cepero M. Monitoring cell-mediated immunity during immunosuppression reduction in heart transplant recipients with severe systemic infections. *Clin Transplant*. 2020;34(3):e13809. doi:10.1111/ctr.13809
  25. Rodrigo E, Lopez-Hoyos M, Corral M, et al. ImmuKnow as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: a systematic review and meta-analysis. *Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society*. 2012;18(10):1245-53. doi:10.1002/lt.23497
  26. Clark N, Cotler SJ. Infectious complications in liver transplantation. Updated August 1, 2025. <https://www.uptodate.com/contents/infectious-complications-in-liver-transplantation>
  27. Monforte V, Ussetti P, Castejón R, et al. Predictive Value of Immune Cell Functional Assay for Non-Cytomegalovirus Infection in Lung Transplant Recipients: A Multicenter Prospective Observational Study. *Archivos de Bronconeumología*. 2021;doi:10.1016/j.arbres.2020.12.024
  28. Xue F, Gao W, Qin T, et al. Immune cell function assays in the diagnosis of infection in pediatric liver transplantation: an open-labeled, two center prospective cohort study. *Transl Pediatr*. 2021;10(2):333-343. doi:10.21037/tp-20-256
  29. Maidman SD, Gidea C, Reyentovich A, et al. Pre-transplant immune cell function assay as a predictor of early cardiac allograft rejection. *Clin Transplant*. 2022;36(7):e14745. doi:10.1111/ctr.14745
  30. Chen JK, Salerno DM, Corbo H, et al. Immune cell function assay and T lymphocyte counts lack association with rejection or infection in pediatric heart transplant recipients. *Clin Transplant*. 2023;37(2):e14858. doi:10.1111/ctr.14858
  31. Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients. *The Journal of Heart and Lung Transplantation*. 2022;0(0)doi:10.1016/j.healun.2022.09.023
  32. Kobashigawa J, Colvin M, Potena L, et al. The management of antibodies in heart transplantation: An ISHLT consensus document. *J Heart Lung Transplant*. 2018;37(5):537-547. doi:10.1016/j.healun.2018.01.1291
  33. Levine DJ, Glanville AR, Aboyoun C, et al. Antibody-mediated rejection of the lung: A consensus report of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant*. 2016;35(4):397-406. doi:10.1016/j.healun.2016.01.1223
  34. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2006;6(2):262-74. doi:10.1111/j.1600-6143.2005.01207.x
  35. AST. Guidelines for Post-Kidney Transplant Management in the Community Setting. 2009;

36. Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. *Clinical Transplantation*. 2019;33(9):e13512. doi:10.1111/ctr.13512
37. Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation. *Transplantation*. 2018;102(6):900-931. doi:10.1097/tp.0000000000002191
38. Alexandra YK, Fatima D, Aisling MF, et al. European Society for Immunodeficiencies guidelines for the management of patients with congenital athymia. *Journal of Allergy and Clinical Immunology*. 2024;154(6):1391-1408. doi:10.1016/j.jaci.2024.07.031

### Policy Update History:

| Approval Date | Effective Date; Summary of Revisions                                                                                                                                                                                                                |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 01/12/2026    | 05/01/2026; Document updated with literature review. The following change was made to Reimbursement Information: Revised #2 for clarity to state “An immune cell function assay is not reimbursable for all other indications.” References revised. |
| 01/23/2025    | 04/15/2025; Document updated with literature review. Reimbursement Information unchanged. References revised.                                                                                                                                       |
| 02/01/2024    | Document updated with literature review. Reimbursement Information unchanged. References revised.                                                                                                                                                   |
| 11/01/2023    | Document updated with literature review. Reimbursement information unchanged. References revised.                                                                                                                                                   |
| 11/01/2022    | New policy                                                                                                                                                                                                                                          |